# ALICIA (Acalabrutinib in CLL Therapy)

> **NCT04746950** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 90 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04746950
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-03
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04746950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04746950, "ALICIA (Acalabrutinib in CLL Therapy)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04746950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*